FFO and Guidance Maintained
First-quarter FFO of $20.0M, or $0.11 per share, in line with consensus and management guidance; full-year FFO midpoint maintained at $0.55 with narrowed guidance range.
Strong Spec Leasing and Tour Activity
Achieved 94% of the speculative revenue target (target = $400,000); tours in 2026 exceeded 2025 by 80% with a 53% tours→proposal conversion and a 37% proposal→lease conversion (trailing four quarters).
Solid Leasing and Occupancy Metrics
Wholly owned core portfolio 88.3% occupied and 89.9% leased; Q1 leasing activity totaled 422,000 sq ft (268k wholly owned — highest since 2024 — and 153k JV); forward leasing after year-end of 182,000 sq ft.
Outperformance in Philadelphia
Philadelphia portfolio at ~94% occupied and 96% leased; Commerce Square JV 93% leased, combined Philadelphia holdings ~95% leased; captured ~41% of new leases in the market in 2026 (more than double market share over past five years).
Meaningful Sales Pipeline to Reduce Leverage
Approximately $305M of potential sales under agreement and in due diligence (in line with guidance), with expectation that majority will close in Q2; business plan projects $280M–$300M of sales activity.
Improving Same-Store and NOI Results
Same-store results were +0.8% GAAP and +3.3% cash (both above guidance ranges); property-level NOI $70.2M, $0.8M above reforecast due to better margins.
Development & Project Leasing Momentum
3151 Market pipeline up to ~1.2M sq ft (up 200k from prior quarter; ~50% office / 50% life science); One Uptown 63% leased (up from prior quarter) with pipeline >230k sq ft and six proposals ~100k sq ft; generated ~1.2M additional sq ft of prospects since project marketing launch.
Planned Refinancing and Capital Actions
Plan to repay 3025 JFK construction loan with ~ $100M seven-year financing at mid-5% (expected to unencumber office portion); about 50% of outstanding bonds have coupons >8%, creating refinancing opportunities; opportunistic share repurchase capacity ~$82M available.